Metformin effects revisited

Diabetes Research and Clinical Practice

Volumn 95, Issue 1, 2012, Pages 1-9

  Andujar Plata P ^a   Pi Sunyer, X ^b   Laferrere B ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Biguanides; Cancer; Metformin; Type 2 diabetes

Indexed keywords

AMYLOID; FATTY ACID SYNTHASE; G PROTEIN COUPLED RECEPTOR; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INCRETIN; INSULIN; MAMMALIAN TARGET OF RAPAMYCIN; MEGLITINIDE; METFORMIN; SULFONYLUREA DERIVATIVE;

ANEMIA; ANTINEOPLASTIC ACTIVITY; BILE ACID METABOLISM; CANCER INCIDENCE; CANCER REGISTRY; CELL CYCLE ARREST; CELL PROLIFERATION; COST EFFECTIVENESS ANALYSIS; DIABETIC RETINOPATHY; DIET THERAPY; DNA SYNTHESIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EPITHELIAL MESENCHYMAL TRANSITION; EXERCISE; GASTROINTESTINAL SYMPTOM; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; GLYCEMIC CONTROL; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LACTIC ACIDOSIS; LIFESTYLE MODIFICATION; MOLECULAR DYNAMICS; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET; PROSPECTIVE STUDY; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN SYNTHESIS; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; TREATMENT OUTCOME;

EID: 84355166626     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.09.022     Document Type: Review

References (74)

1. International Diabetes Federation Diabetes atlas 2009, International Diabetes Federation, Brussels. fourth ed.
2. Kirpichnikov D., McFarlane S.I., Sowers J.R. Metformin: an update. Ann Intern Med 2002, 137:25-33.
3. Stumvoll M., Nurjhan N., Perriello G., Dailey G., Gerich J.E. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995, 333:550-554.
4. DeFronzo R.A., Goodman A.M. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995, 333:541-549.
5. The global challenge of diabetes. Lancet 2008, 371:1723.
6. Campbell I.W., Howlett H.C. Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis. Diabetes Metab Rev 1995, 11(Suppl. 1):S57-S62.
7. Bailey C.J., Turner R.C. Metformin. N Engl J Med 1996, 334:574-579.
8. UK Prospective Diabetes Study (UKPDS) VIII. Study design, progress and performance. Diabetologia 1991, 34:877-890.
9. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
10. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
11. United Kingdom Prospective Diabetes Study (UKPDS) 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995, 310:83-88.
12. Wright A.D., Cull C.A., Macleod K.M., Holman R.R. Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. J Diabetes Complications 2006, 20:395-401.
13. Turner R.C., Cull C.A., Frighi V., Holman R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999, 281:2005-2012.
14. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:854-865.
15. Clarke P., Gray A., Adler A., Stevens R., Raikou M., Cull C., et al. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51). Diabetologia 2001, 44:298-304.
16. Ong C.R., Molyneaux L.M., Constantino M.I., Twigg S.M., Yue D.K. Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes. Diabetes Care 2006, 29:2361-2364.
17. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
18. Diabetes Prevention Program Research Group Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care 2003, 26:2518-2523.
19. Fujimoto W.Y., Jablonski K.A., Bray G.A., Kriska A., Barrett-Connor E., Haffner S., et al. Body size and shape changes and the risk of diabetes in the Diabetes Prevention Program. Diabetes 2007, 56:1680-1685.
20. Lachin J.M., Christophi C.A., Edelstein S.L., Ehrmann D.A., Hamman R.F., Kahn S.E., et al. Factors associated with diabetes onset during metformin versus placebo therapy in the Diabetes Prevention Program. Diabetes 2007, 56:1153-1159.
21. Ratner R.E., Christophi C.A., Metzger B.E., Dabelea D., Bennett P.H., Pi-Sunyer X., et al. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endocrinol Metab 2008, 93:4774-4779.
22. Perreault L., Kahn S.E., Christophi C.A., Knowler W.C., Hamman R.F. Regression from pre-diabetes to normal glucose regulation in the Diabetes Prevention Program. Diabetes Care 2009, 32:1583-1588.
23. Kitabchi A.E., Temprosa M., Knowler W.C., Kahn S.E., Fowler S.E., Haffner S.M., et al. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the Diabetes Prevention Program: effects of lifestyle intervention and metformin. Diabetes 2005, 54:2404-2414.
24. Orchard T.J., Temprosa M., Goldberg R., Haffner S., Ratner R., Marcovina S., et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005, 142:611-619.
25. Haffner S., Temprosa M., Crandall J., Fowler S., Goldberg R., Horton E., et al. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2005, 54:1566-1572.
26. Ratner R., Goldberg R., Haffner S., Marcovina S., Orchard T., Fowler S., et al. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care 2005, 28:888-894.
27. Knowler W.C., Fowler S.E., Hamman R.F., Christophi C.A., Hoffman H.J., Brenneman A.T., et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009, 374:1677-1686.
28. Salpeter S.R., Greyber E., Pasternak G.A., Salpeter E.E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010, CD002967.
29. Scarpello J.H., Howlett H.C. Metformin therapy and clinical uses. Diab Vasc Dis Res 2008, 5:157-167.
30. Gunton J.E., Delhanty P.J., Takahashi S., Baxter R.C. Metformin rapidly increases insulin receptor activation in human liver and signals preferentially through insulin-receptor substrate-2. J Clin Endocrinol Metab 2003, 88:1323-1332.
31. Luo Z., Zang M., Guo W. AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol 2010, 6:457-470.
32. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001, 108:1167-1174.
33. Yoshida T., Okuno A., Tanaka J., Takahashi K., Nakashima R., Kanda S., et al. Metformin primarily decreases plasma glucose not by gluconeogenesis suppression but by activating glucose utilization in a non-obese type 2 diabetes Goto-Kakizaki rats. Eur J Pharmacol 2009, 623:141-147.
34. Zou M.H., Kirkpatrick S.S., Davis B.J., Nelson J.S., Wiles W.G., Schlattner U., et al. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J Biol Chem 2004, 279:43940-43951.
35. Fujita Y., Hosokawa M., Fujimoto S., Mukai E., Abudukadier A., Obara A., et al. Metformin suppresses hepatic gluconeogenesis and lowers fasting blood glucose levels through reactive nitrogen species in mice. Diabetologia 2010, 53:1472-1481.
36. Foretz M., Hebrard S., Leclerc J., Zarrinpashneh E., Soty M., Mithieux G., et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010, 120:2355-2369.
37. Maida A., Lamont B.J., Cao X., Drucker D.J. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-alpha in mice. Diabetologia 2011, 54:339-349.
38. Scarpello J.H., Hodgson E., Howlett H.C. Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus. Diabet Med 1998, 15:651-656.
39. Carter D., Howlett H.C., Wiernsperger N.F., Bailey C.J. Differential effects of metformin on bile salt absorption from the jejunum and ileum. Diabetes Obes Metab 2003, 5:120-125.
40. Carter D., Howlett H.C., Wiernsperger N.F., Bailey C. Effects of metformin on bile salt transport by monolayers of human intestinal Caco-2 cells. Diabetes Obes Metab 2002, 4:424-427.
41. Thomas C., Gioiello A., Noriega L., Strehle A., Oury J., Rizzo G., et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009, 10:167-177.
42. Patti M.E., Houten S.M., Bianco A.C., Bernier R., Larsen P.R., Holst J.J., et al. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring) 2009, 17:1671-1677.
43. Hull R.L., Shen Z.P., Watts M.R., Kodama K., Carr D.B., Utzschneider K.M., et al. Long-term treatment with rosiglitazone and metformin reduces the extent of, but does not prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide. Diabetes 2005, 54:2235-2244.
44. Saydah S.H., Loria C.M., Eberhardt M.S., Brancati F.L. Abnormal glucose tolerance and the risk of cancer death in the United States. Am J Epidemiol 2003, 157:1092-1100.
45. Michels K.B., Solomon C.G., Hu F.B., Rosner B.A., Hankinson S.E., Colditz G.A., et al. Type 2 diabetes and subsequent incidence of breast cancer in the Nurses Health Study. Diabetes Care 2003, 26:1752-1758.
46. La Vecchia C., Negri E., Franceschi S., D'Avanzo B., Boyle P. A case-control study of diabetes mellitus and cancer risk. Br J Cancer 1994, 70:950-953.
47. Evans J.M., Donnelly L.A., Emslie-Smith A.M., Alessi D.R., Morris A.D. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005, 330:1304-1305.
48. Bowker S.L., Majumdar S.R., Veugelers P., Johnson J.A. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006, 29:254-258.
49. Libby G., Donnelly L.A., Donnan P.T., Alessi D.R., Morris A.D., Evans J.M. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009, 32:1620-1625.
50. Monami M., Colombi C., Balzi D., Dicembrini I., Giannini S., Melani C., et al. Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 2011, 34:129-131.
51. Landman G.W., Kleefstra N., van Hateren K.J., Groenier K.H., Gans R.O., Bilo H.J. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010, 33:322-326.
52. Hosono K., Endo H., Takahashi H., Sugiyama M., Sakai E., Uchiyama T., et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila) 2010, 3:1077-1083.
53. Home P.D., Kahn S.E., Jones N.P., Noronha D., Beck-Nielsen H., Viberti G. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 2010, 53:1838-1845.
54. Jiralerspong S., Palla S.L., Giordano S.H., Meric-Bernstam F., Liedtke C., Barnett C.M., et al. 2009 Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009, 27:3297-3302.
55. Bodmer M., Meier C., Krahenbuhl S., Jick S.S., Meier C.R. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010, 33:1304-1308.
56. Li D., Yeung S.C., Hassan M.M., Konopleva M., Abbruzzese J.L. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009, 137:482-488.
57. Wright J.L., Stanford J.L. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control 2009, 20:1617-1622.
58. He X.X., Tu S.M., Lee M.H., Yeung S.C. Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol 2011, Epub ahead of print.
59. Vazquez-Martin A., Oliveras-Ferraros C., Menendez J.A. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle 2009, 8:88-96.
60. Alimova I.N., Liu B., Fan Z., Edgerton S.M., Dillon T., Lind S.E., et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009, 8:909-915.
61. Hirsch H.A., Iliopoulos D., Tsichlis P.N., Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009, 69:7507-7511.
62. Vazquez-Martin A., Oliveras-Ferraros C., Cufi S., Del Barco S., Martin-Castillo B., Menendez J.A. Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle 2010, 9:3807-3814.
63. Liu B., Fan Z., Edgerton S.M., Deng X.S., Alimova I.N., Lind S.E., et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 2009, 8:2031-2040.
64. Maatela J., Aromaa A., Salmi T., Pohja M., Vuento M., Gronroos M. The risk of endometrial cancer in diabetic and hypertensive patients: a nationwide record-linkage study in Finland. Ann Chir Gynaecol Suppl 1994, 208:20-24.
65. Cantrell L.A., Zhou C., Mendivil A., Malloy K.M., Gehrig P.A., Bae-Jump V.L. Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy. Gynecol Oncol 2010, 116:92-98.
66. Tan B.K., Adya R., Chen J., Lehnert H., Sant Cassia L.J., Randeva H.S. Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells. J Clin Endocrinol Metab 2011, 96:808-816.
67. Rattan R., Giri S., Hartmann L.C., Shridhar V. Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med 2011, 15:166-178.
68. Yasmeen A., Beauchamp M.C., Piura E., Segal E., Pollak M., Gotlieb W.H. Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins. Gynecol Oncol 2011, Epub ahead of print.
69. Kisfalvi K., Eibl G., Sinnett-Smith J., Rozengurt E. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 2009, 69:6539-6545.
70. Algire C., Amrein L., Zakikhani M., Panasci L., Pollak M. Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer 2010, 17:351-360.
71. Algire C., Zakikhani M., Blouin M.J., Shuai J.H., Pollak M. Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer 2008, 15:833-839.
72. Memmott R.M., Mercado J.R., Maier C.R., Kawabata S., Fox S.D., Dennis P.A. Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev Res (Phila) 2010, 3:1066-1076.
73. Iliopoulos D., Hirsch H.A., Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res 2011, 71:3196-3201.
74. Anisimov V.N., Berstein L.M., Popovich I.G., Zabezhinski M.A., Egormin P.A., Piskunova T.S., et al. If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice. Aging (Albany, NY) 2011, 3:148-157.